AR054215A1 - Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit - Google Patents

Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Info

Publication number
AR054215A1
AR054215A1 AR20060100208A ARP060100208A AR054215A1 AR 054215 A1 AR054215 A1 AR 054215A1 AR 20060100208 A AR20060100208 A AR 20060100208A AR P060100208 A ARP060100208 A AR P060100208A AR 054215 A1 AR054215 A1 AR 054215A1
Authority
AR
Argentina
Prior art keywords
taxane
composition
solid composition
acetic acid
solution
Prior art date
Application number
AR20060100208A
Other languages
English (en)
Spanish (es)
Inventor
Nora Moyano
Jose Iturraspe
Jose Lucio Nunez
Original Assignee
Eriochem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054215(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eriochem Sa filed Critical Eriochem Sa
Priority to AR20060100208A priority Critical patent/AR054215A1/es
Priority to JP2008550785A priority patent/JP2009523770A/ja
Priority to BRPI0706931-6A priority patent/BRPI0706931A2/pt
Priority to PCT/ES2007/070012 priority patent/WO2007082978A1/es
Priority to RU2008133761/15A priority patent/RU2429837C2/ru
Priority to US12/161,625 priority patent/US20090215883A1/en
Priority to EP07712569A priority patent/EP1994925A4/en
Priority to MX2008009358A priority patent/MX2008009358A/es
Priority to AU2007206876A priority patent/AU2007206876B2/en
Priority to NZ569783A priority patent/NZ569783A/en
Priority to CA002637893A priority patent/CA2637893A1/en
Priority to ZA200805704A priority patent/ZA200805704B/xx
Priority to PE2007000062A priority patent/PE20070945A1/es
Priority to CA002638034A priority patent/CA2638034A1/en
Priority to BRPI0706932-4A priority patent/BRPI0706932A2/pt
Priority to PCT/ES2007/070013 priority patent/WO2007082979A1/es
Priority to MX2008009357A priority patent/MX2008009357A/es
Priority to UY30099A priority patent/UY30099A1/es
Priority to US12/161,609 priority patent/US20090215882A1/en
Priority to AU2007206877A priority patent/AU2007206877A1/en
Priority to NZ569968A priority patent/NZ569968A/en
Priority to PE2007000063A priority patent/PE20071243A1/es
Priority to EP07712570A priority patent/EP1982699A1/en
Priority to JP2008550786A priority patent/JP2009523771A/ja
Priority to UY30100A priority patent/UY30100A1/es
Publication of AR054215A1 publication Critical patent/AR054215A1/es
Priority to ZA200805989A priority patent/ZA200805989B/xx
Priority to GT200800145A priority patent/GT200800145A/es
Priority to GT200800146A priority patent/GT200800146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
AR20060100208A 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit AR054215A1 (es)

Priority Applications (28)

Application Number Priority Date Filing Date Title
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CA002637893A CA2637893A1 (en) 2006-01-20 2007-01-18 Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
RU2008133761/15A RU2429837C2 (ru) 2006-01-20 2007-01-18 Фармацевтический состав таксана, твердая композиция таксана, способ получения твердой композиции таксана, композиция для солюбилизации указанной твердой композиции таксана и комплект элементов (набор) для состава таксана для инъекций
BRPI0706931-6A BRPI0706931A2 (pt) 2006-01-20 2007-01-18 uma formulação farmacêutica que compreende um taxano, uma composição sólida de taxano, um processo para preparar dita composição sólida de taxano, uma composição de solubulização de dita composição de taxano, e um kit de formulação injetável de taxano
PCT/ES2007/070012 WO2007082978A1 (es) 2006-01-20 2007-01-18 Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par
JP2008550785A JP2009523770A (ja) 2006-01-20 2007-01-18 タキサン医薬製剤、固形タキサン組成物、前記固形タキサン組成物の調製方法、前記固形タキサン組成物を可溶化するための組成物および注射可能なタキサン製剤のための構成要素のセット（キット）
US12/161,625 US20090215883A1 (en) 2006-01-20 2007-01-18 Pharmaceutical formulation comprising taxane, a solid composition of taxane, a process for preparing said solid composition of taxane, a solubilizing composition of said solid composition of taxane, and a kit for the injectable formulation of taxane
EP07712569A EP1994925A4 (en) 2006-01-20 2007-01-18 PHARMACEUTICAL TAX FORMULATION, TAXAN SOLID-MATERIAL COMPOSITION, METHOD FOR PRODUCING TAXAN SOLID-MATERIAL COMPOSITION, COMPOSITION FOR SOLUBILIZING THE TAXAN SOLID-MATERIAL COMPOSITION, AND ELEMENT SET (KIT) FOR INJECTABLE TAX FORMULATION
MX2008009358A MX2008009358A (es) 2006-01-20 2007-01-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubllizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
AU2007206876A AU2007206876B2 (en) 2006-01-20 2007-01-18 Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
NZ569783A NZ569783A (en) 2006-01-20 2007-01-18 Surfactant-free freeze-dried solid taxane composition
UY30100A UY30100A1 (es) 2006-01-20 2007-01-19 Una formulacion farmacéutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
NZ569968A NZ569968A (en) 2006-01-20 2007-01-19 A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
ZA200805704A ZA200805704B (en) 2006-01-20 2007-01-19 A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
CA002638034A CA2638034A1 (en) 2006-01-20 2007-01-19 A lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit of said formulation
BRPI0706932-4A BRPI0706932A2 (pt) 2006-01-20 2007-01-19 composição sólida de taxano liofilizada, procedimento para preparar dita composição sólida, formulação farmaçêutica e conjunto (kit) de dita formulação
PCT/ES2007/070013 WO2007082979A1 (es) 2006-01-20 2007-01-19 Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación
MX2008009357A MX2008009357A (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
UY30099A UY30099A1 (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizado, un procedimiento para preparar dicha composicion solida, una formulacion farmacéutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano
US12/161,609 US20090215882A1 (en) 2006-01-20 2007-01-19 Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
AU2007206877A AU2007206877A1 (en) 2006-01-20 2007-01-19 A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
PE2007000062A PE20070945A1 (es) 2006-01-20 2007-01-19 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
PE2007000063A PE20071243A1 (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano
EP07712570A EP1982699A1 (en) 2006-01-20 2007-01-19 A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
JP2008550786A JP2009523771A (ja) 2006-01-20 2007-01-19 凍結乾燥した個体状タキサン類組成物、前記組成物を生成する方法、前記組成物の医薬調剤、前記組成物の調剤用キット。
ZA200805989A ZA200805989B (en) 2006-01-20 2008-07-09 Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
GT200800145A GT200800145A (es) 2006-01-20 2008-07-18 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion
GT200800146A GT200800146A (es) 2006-01-20 2008-07-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Publications (1)

Publication Number Publication Date
AR054215A1 true AR054215A1 (es) 2007-06-13

Family

ID=38134453

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Country Status (15)

Country Link
US (2) US20090215883A1 (https=)
EP (2) EP1994925A4 (https=)
JP (2) JP2009523770A (https=)
AR (1) AR054215A1 (https=)
AU (1) AU2007206877A1 (https=)
BR (2) BRPI0706931A2 (https=)
CA (2) CA2637893A1 (https=)
GT (2) GT200800146A (https=)
MX (2) MX2008009358A (https=)
NZ (2) NZ569783A (https=)
PE (2) PE20070945A1 (https=)
RU (1) RU2429837C2 (https=)
UY (2) UY30100A1 (https=)
WO (2) WO2007082978A1 (https=)
ZA (2) ZA200805704B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
BRPI0406647A (pt) 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US7557182B2 (en) 2005-02-18 2009-07-07 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
JP2010524919A (ja) * 2007-04-23 2010-07-22 サン、ファーマスーティカル、インダストリーズ、リミテッド 医薬組成物
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
TR201905480T4 (tr) * 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
WO2011082369A2 (en) * 2009-12-31 2011-07-07 Mannkind Corporation Injectable formulations for parenteral administration
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2958554B1 (en) * 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP2985038A1 (en) * 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
TWI838700B (zh) 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
RU2708329C2 (ru) * 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
US11957758B2 (en) * 2017-09-07 2024-04-16 Shenzhen Salubris Pharmaceuticals Co. Ltd. Pharmaceutical composition of docetaxel conjugate and preparation method
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
CN107496352A (zh) * 2017-10-13 2017-12-22 深圳万乐药业有限公司 一种多烯紫杉醇药物组合物及其制备方法
EP3827822B1 (en) * 2018-07-25 2024-11-06 Bika Biotechnology (Guangzhou) Co., Ltd. Docetaxel composition for injection and preparation method therefor
PE20220250A1 (es) 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2371836C (en) * 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
ATE555773T1 (de) 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
US20010047162A1 (en) * 2000-02-17 2001-11-29 Yasumi Yugari Injection kit and injection device
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US7550157B2 (en) * 2000-05-12 2009-06-23 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US6759539B1 (en) * 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN1850056A (zh) * 2006-03-06 2006-10-25 杨典忠 多西他赛冻干粉针及其制备方法
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano

Also Published As

Publication number Publication date
RU2008133761A (ru) 2010-02-27
PE20070945A1 (es) 2007-10-07
MX2008009358A (es) 2008-09-10
JP2009523771A (ja) 2009-06-25
NZ569968A (en) 2011-07-29
PE20071243A1 (es) 2008-02-03
BRPI0706932A2 (pt) 2011-04-19
BRPI0706931A2 (pt) 2011-04-19
MX2008009357A (es) 2008-09-10
RU2429837C2 (ru) 2011-09-27
AU2007206877A1 (en) 2007-07-26
ZA200805989B (en) 2009-05-27
CA2637893A1 (en) 2007-07-26
GT200800146A (es) 2008-12-15
WO2007082978A1 (es) 2007-07-26
ZA200805704B (en) 2009-11-25
US20090215882A1 (en) 2009-08-27
UY30099A1 (es) 2008-09-02
EP1982699A1 (en) 2008-10-22
UY30100A1 (es) 2008-09-02
GT200800145A (es) 2009-07-21
CA2638034A1 (en) 2007-07-26
EP1994925A1 (en) 2008-11-26
NZ569783A (en) 2011-04-29
EP1994925A4 (en) 2013-01-23
WO2007082979A1 (es) 2007-07-26
JP2009523770A (ja) 2009-06-25
WO2007082978B1 (es) 2007-09-07
US20090215883A1 (en) 2009-08-27
AU2007206876A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
AR054215A1 (es) Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
Han et al. Melatonin facilitates adipose‐derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway
ECSP099642A (es) Formulaciones estables de anticuerpo
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
ES2572267T3 (es) Composiciones de insulina de acción súper rápida
MY152013A (en) Stabilized single-liquid pharmaceutical composition containing docetaxel
PE20030802A1 (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido
AR107285A2 (es) Vacuna
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
AR062760A1 (es) Administracion de inhibidores de dipeptidilpetidasa
ECSP088962A (es) Nuevos herbicidas
AR050918A1 (es) Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
CL2011003192A1 (es) Acido (2s)-3-(2-fluoro-5-(5-fluoro-1h-pirrolo[2,3-b]piridin-3-il)fenilamino)biciclo[2.2.2]octano-2-carboxilico; metodo para prepararlo; composicion farmaceutica que lo comprende; y su uso en el tratamiento de la influenza; metodo para reducir el virus de la influenza in vitro.
AR050353A1 (es) Composicion de anticuerpo her2
AR063587A1 (es) Preparcion liquida que comprende pimobendan
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης

Legal Events

Date Code Title Description
FB Suspension of granting procedure